mRNA-4157

Cancer vaccines are gaining momentum across multiple tumor types, with FDA-approved options like BCG, sipuleucel-T, and talimogene laherparepvec demonstrating clinical utility in bladder cancer, prostate cancer, and melanoma respectively.

Personalized cancer vaccines are emerging as a transformative approach in oncology, with BioNTech, Moderna, and myNEO Therapeutics leading development using mRNA technology refined during the COVID-19 pandemic.

Moderna and Merck's personalized cancer vaccine mRNA-4157, combined with Keytruda, demonstrated a 65% reduction in risk of distant metastasis or death in high-risk melanoma patients.

Breakthrough developments in genomic sequencing have enabled the identification of tumor-specific neoantigens, revolutionizing the approach to personalized cancer vaccine development.

BioNTech's mRNA-based cancer vaccine BNT111, combined with Regeneron's Libtayo, demonstrated significant improvement in overall response rate for advanced melanoma patients who failed prior immunotherapy.